Sensory improvement of leprosy peripheral neuropathy in patients treated with perineural injection of platelet-rich plasma

Anjayani, Sukma; Wirohadidjojo, Yohanes Widodo; Adam, Andi Muhammad; Suwandi, Danny; Seweng, Arifin; Amiruddin, Muh Dali

doi:10.1111/ijd.12162

Cited by 86 publications

(60 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2014, Anjayani et al . 17 first reported a randomized, double-blind, control trial study to prove that a 1-mL PRP perineural injection could improve pain scores using a VAS, and the two-point discrimination test of peripheral neuropathy, in patients with Hansen’s disease compared with a 1-mL PPP injection, 2 weeks after the injection of both types of plasma (n = 30 vs. n = 30, respectively). Subsequently, Sánchez et al .…”

Section: Discussionmentioning

confidence: 99%

“…Recently, increasing evidence has revealed the beneficial effects of PRP on axon regeneration and neurological recovery in animal or vitro studies 9–16 . Since 2014, a few studies have applied PRP for treating clinical peripheral neuropathy, with acceptable success rates 17–21 . Among these studies, there was one pilot study and one small, non-randomized trial enrolling patients with CTS.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial

Wu¹,

Ho²,

Chou³

et al. 2017

Sci Rep

163

View full text Add to dashboard Cite

Recently, a few small reports with short follow-up period have shown clinical benefits of platelet-rich plasma (PRP) for peripheral neuropathy including one pilot study and one small, non-randomized trial in patients with carpal tunnel syndrome (CTS). Therefore, we conducted a randomized, single-blind, controlled trial to assess the 6-month effect of PRP in patients with CTS. Sixty patients with unilateral mild-to-moderate CTS were randomized into two groups of 30, namely the PRP and control groups. In the PRP group, patients were injected with one dose of 3 mL of PRP using ultrasound guidance and the control group received a night splint through the study period. The primary outcome measure was the visual analog scale (VAS) and secondary outcome measures included the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) score, the cross-sectional area (CSA) of the median nerve (MN), electrophysiological findings of the MN, and finger pinch strength. The evaluation was performed before treatment and at 1, 3, and 6 months post-injection. The PRP group exhibited a significant reduction in the VAS score, BCTQ score, and CSA of MN compared to the those of control group 6 months post-treatment (p < 0.05). Our study demonstrates that PRP is a safe modality that effectively relieves pain and improves disability in the patients with CTS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial

Wu¹,

Ho²,

Chou³

et al. 2017

Sci Rep

163

View full text Add to dashboard Cite

show abstract

“…There are numerous studies in the literature illustrating the effects of PRP on skin, muscle, ligaments, bone, bowel, peripheral nerves, trachea, ovary, heart, liver, brain and cornea [20–25, 29, 41–44]. However, to the best of our knowledge, this is the first study to evaluate the effects of PRP on the kidney.…”

Section: Discussionmentioning

confidence: 99%

“…The SALINE Group rats were injected with 1mL of saline following the same protocol. The dose of PRP used in other experimental studies varies greatly, ranging from 0.05mL to 5mL [21, 29–34]. Since there is no guidance in the literature on PRP dosing in rat kidneys, a pilot study was conducted on four rats before starting the present study.…”

Section: Methodsmentioning

confidence: 99%

Effects of Platelet-Rich Plasma (PRP) on a Model of Renal Ischemia-Reperfusion in Rats

et al. 2016

View full text Add to dashboard Cite

Renal ischemia-reperfusion injury is a major cause of acute renal failure, causing renal cell death, a permanent decrease of renal blood flow, organ dysfunction and chronic kidney disease. Platelet-rich plasma (PRP) is an autologous product rich in growth factors, and therefore able to promote tissue regeneration and angiogenesis. This product has proven its efficacy in multiple studies, but has not yet been tested on kidney tissue. The aim of this work is to evaluate whether the application of PRP to rat kidneys undergoing ischemia-reperfusion reduces mid-term kidney damage. A total of 30 monorrenal Sprague-Dawley male rats underwent renal ischemia-reperfusion for 45 minutes. During ischemia, PRP (PRP Group, n = 15) or saline solution (SALINE Group, n = 15) was administered by subcapsular renal injection. Control kidneys were the contralateral organs removed immediately before the start of ischemia in the remaining kidneys. Survival, body weight, renal blood flow on Doppler ultrasound, kidney weight, kidney volume, blood biochemistry and histopathology were determined for all subjects and kidneys, as applicable. Correlations between these variables were searched for. The PRP Group showed significantly worse kidney blood flow (p = 0.045) and more histopathological damage (p<0.0001). Correlations were found between body weight, kidney volume, kidney weight, renal blood flow, histology, and serum levels of creatinine and urea. Our study provides the first evidence that treatment with PRP results in the deterioration of the kidney’s response to ischemia-reperfusion injury.

show abstract

“…The injection of PRP to sites of peripheral neuropathies associated with leprosy induces nerve regeneration and the reestablishment of some sensitivity [242].…”

Section: Clinical: Improvementmentioning

confidence: 99%

Platelet-Rich Plasma Promotes Axon Regeneration, Wound Healing, and Pain Reduction: Fact or Fiction

Kuffler

2015

Mol Neurobiol

View full text Add to dashboard Cite

Platelet-rich plasma (PRP) has been tested in vitro, in animal models, and clinically for its efficacy in enhancing the rate of wound healing, reducing pain associated with injuries, and promoting axon regeneration. Although extensive data indicate that PRP-released factors induce these effects, the claims are often weakened because many studies were not rigorous or controlled, the data were limited, and other studies yielded contrary results. Critical to assessing whether PRP is effective are the large number of variables in these studies, including the method of PRP preparation, which influences the composition of PRP; type of application; type of wounds; target tissues; and diverse animal models and clinical studies. All these variables raise the question of whether one can anticipate consistent influences and raise the possibility that most of the results are correct under the circumstances where PRP was tested. This review examines evidence on the potential influences of PRP and whether PRP-released factors could induce the reported influences and concludes that the preponderance of evidence suggests that PRP has the capacity to induce all the claimed influences, although this position cannot be definitively argued. Well-defined and rigorously controlled studies of the potential influences of PRP are required in which PRP is isolated and applied using consistent techniques, protocols, and models. Finally, it is concluded that, because of the purported benefits of PRP administration and the lack of adverse events, further animal and clinical studies should be performed to explore the potential influences of PRP.

show abstract

Sensory improvement of leprosy peripheral neuropathy in patients treated with perineural injection of platelet-rich plasma

Abstract: This study shows that perineural PRP injection could promote improvement of peripheral neuropathy sensibility in patients with leprosy. More research is needed to better determine the effects of PRP in nerve regeneration.

Cited by 86 publications

References 21 publications

Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial

Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial

Effects of Platelet-Rich Plasma (PRP) on a Model of Renal Ischemia-Reperfusion in Rats

Platelet-Rich Plasma Promotes Axon Regeneration, Wound Healing, and Pain Reduction: Fact or Fiction

Contact Info

Product

Resources

About